Cardiac Surgery Unit, Department of Cardiovascular Sciences, University of Leicester, UK.
J Surg Res. 2012 May 1;174(1):e1-e10. doi: 10.1016/j.jss.2011.09.050. Epub 2011 Oct 18.
The myocardium of patients with diabetes and poor left ventricular (LV) function cannot be protected by interventions such as ischemic preconditioning (IP). We investigated whether these clinical conditions influence the protection elicited by the paracrine effect of bone marrow cells (BMCs) and whether the cause for loss in protection resides in the BMCs, the myocardium, or both.
BMCs and right atrial appendage were obtained from patients with and without diabetes and from poor (EF < 30%) and preserved LV function undergoing elective cardiac surgery. Muscles (n = 6/group) were co-cultured with BMCs and subjected to 90 min ischemia/120 min reoxygenation at 37°C. The degree of protection was assessed by measuring creatine kinase (CK) released, and myocardial cell necrosis and apoptosis.
Ischemia-induced CK release, cell necrosis, and apoptosis in the diabetic myocardium were not significantly affected by IP or by co-incubation with autologous or non-diabetic allogenic BMCs. Conversely, significant reduction in CK release, cell necrosis, and apoptosis were observed when non-diabetic myocardium was co-incubated with allogenic diabetic BMCs. Interestingly, while allogenic BMCs from subjects with preserved LV function exerted a modest but significant reduction in CK leakage and cell necrosis, but not apoptosis, on failing myocardium, the BMCs from patients with poor LV function failed to protect their own and the allogenic myocardium from subjects with normal LV function.
The failure to protect the myocardium of patients with poor LV function against ischemia/reoxygenation-induced injury is mainly due to a deficit in their BMCs and the myocardium itself, whereas in patients with diabetes the deficit remains within the myocardium and not in the BMCs.
患有糖尿病和左心室(LV)功能不良的患者的心肌不能通过缺血预处理(IP)等干预措施得到保护。我们研究了这些临床情况是否会影响骨髓细胞(BMC)旁分泌作用引起的保护作用,以及保护作用的丧失是源于BMC、心肌还是两者兼而有之。
从接受择期心脏手术的糖尿病患者和非糖尿病患者以及 LV 功能不良(EF<30%)和保存的患者中获得 BMC 和右心房附件。将肌肉(每组 6 个)与 BMC 共培养,并在 37°C 下进行 90 分钟缺血/120 分钟再灌注。通过测量肌酸激酶(CK)释放以及心肌细胞坏死和凋亡来评估保护程度。
糖尿病心肌的缺血诱导 CK 释放、细胞坏死和凋亡不受 IP 或与自体或非糖尿病同种异体 BMC 共孵育的影响。相反,当非糖尿病心肌与同种异体糖尿病 BMC 共孵育时,观察到 CK 释放、细胞坏死和凋亡显著减少。有趣的是,虽然来自 LV 功能正常的患者的同种异体 BMC 对衰竭心肌的 CK 漏出和细胞坏死有适度但显著的降低作用,但对 LV 功能不良患者的自身和同种异体心肌没有保护作用。
LV 功能不良患者的心肌不能防止缺血/再灌注引起的损伤,主要是由于其 BMC 和心肌本身的缺陷所致,而糖尿病患者的缺陷仍然存在于心肌中,而不是在 BMC 中。